The 2012 guidelines for management of heart failure recommend that ACE inhibitors should be used in all patients with an EF ≤ 40% to reduce the risk of HF hospitalization and premature death (CLASS IA).4 However, the guidelines do not mention all-cause mortality. The gene discussed is ACE; the disease is heart failure.